THE ARISING · Longevity & Healthspan
An experimental blood assay tracked advanced tau tangles
Four research cohorts show a promising proxy for advanced pathology, not yet a clinical test.
A new blood assay measured a tau fragment that was more abundant among people with widespread tangles. The researchers call it a proof of principle.
The work, published in JAMA in 2026, is a cross-sectional study of 728 participants in four cohorts. Two were US autopsy cohorts of brain donors who had given blood before death (240 and 241 people). Two were imaging cohorts in Canada and Sweden, where people had plasma samples and tau PET scans. Visits took place between 2002 and 2025, depending on the cohort.
Tau is a protein that forms tangles inside brain cells in Alzheimer's disease. Pathologists grade tangle spread in Braak stages. Stage I means tangles are confined to the entorhinal region, a small area deep in the brain. Stage VI means tangles have spread widely across the neocortex, the brain's outer layer.
The researchers measured a fragment called eMTBR-tau, from the microtubule-binding region of tau, using a new immunoassay. This is a lab format that can be scaled up more easily than mass spectrometry, which earlier work had used to measure the related fragment eMTBR-tau243.
In comparisons across participants in the autopsy cohorts, plasma levels were higher at more advanced Braak stages. In the first cohort, the age- and sex-adjusted geometric mean was 0.0021 pg/mL at stages I-II and 0.107 pg/mL at stage VI, a 50.5-fold difference (95% CI, 26.3-97.0). In the second, it was 0.0040 pg/mL versus 0.101 pg/mL, a 25.2-fold difference (95% CI, 15.8-40.3).
The test was also compared with brain scans. Tau PET shows tangles in living people, and higher uptake values mean more tangles. The study examined how plasma levels related to regional tau-PET uptake and to tau-PET positivity. The immunoassay also correlated strongly with mass spectrometry measurements of eMTBR-tau243.
The authors conclude that the immunoassay identified neocortical tau pathology in both the autopsy and the PET cohorts. They describe the result as a proof of principle that eMTBR-tau can be measured by immunoassay as a marker of advanced tangle pathology.
The authors note that blood biomarkers reflecting tangle burden remain limited. A blood measure of advanced tangles could add to existing tests, and brain imaging is costlier and less widely available.
This study did not follow individual blood levels as disease progressed or show that the assay could guide treatment. Independent validation and prospective clinical testing would be needed before answering either question.